Aging {#S1}
=====

Limited Replicative lifespan was first described by [@B24], who showed that human diploid fibroblasts have a finite capacity for replication after which they enter a metabolically active but irreversibly arrested proliferative state. Aging has been extensively studied in model organisms such as *Caenorhabditis elegans* and is affected by a variety of factors such as stress, nutrient intake, sex, and gene expression ([@B41]). Several genes have been discovered in these relatively simple model organisms such as DAF-2 (insulin/insulin-like growth factor-1 receptor homolog) which, when mutated results in almost doubling the lifespan of *C. elegans* ([@B35]). Success in manipulating lifespan in these model organisms ushered in a massive hunt to discover more aging-related genes, mechanisms and therapeutic compounds. At present, The DrugAge database of aging-related drugs lists around 567 distinct chemical perturbagens that can significantly increase lifespan in a subset of non-disease models spanning over 30 species ([@B5]). Clinical trials such as The Metformin in Longevity Study (MILES) have been launched recently to assess the anti-aging potential of metformin in delaying age-related ailments in humans ([@B15]; [@B50]). One of the essential components for studying aging and age-related diseases in humans are biomarkers that are indicative of chronological age ([@B10]). Recently it has been shown that DNA methylation patterns show a strong correlation with chronological age and this "epigenetic clock" is effective in predicting all-cause mortality with age ([@B29]). Analyzing cancer tissues with this epigenetic clock, composed of methylation levels from 353 CpGs, indicated that tissues from cancer patients treated with various therapies appeared to be an average of 36 years older compared to the actual chronological age of the patients, while induced pluripotent stem cells (iPSCs) from the same individuals showed resetting of the clock to an epigenetic age of zero. However, the biological mechanisms behind this epigenetic biomarker remain unknown, especially, due to a lack of correlation with gene expression data.

Senescence {#S2}
==========

Senescence refers to a state of permanent proliferative arrest characterized by insensitivity to growth factors and mitogens ([@B37]). One of the mechanisms that regulate this insensitivity is dysregulation of normal endocytosis ([@B61]; [@B52]). Senescent cells, were shown to overexpress caveolins, a major component of endocytosis apparatus which prevented their ability to phosphorylate Erk-1/2 phosphorylation post EGF stimulation which was recovered by downregulation via antisense-oligonucleotides. Similar suppression of Erk-1/2 activation was also observed in non-senescent cells post caveolin overexpression ([@B47]; [@B48]). In cell culture, as observed by [@B24], a senescence state is achieved upon repeated passaging, and as shown later, it is mainly due to shortening of telomeric DNA found at the end of chromosomes ([@B23]) that activates an ataxia-telangiectasia mutated (ATM) ([@B58]) and p53-mediated ([@B2]) DNA damage response. This was hypothesized first as the end replication problem; as a consequence of semi-conservative DNA replication and later confirmed by Blackburn, Greider, and Szostak ([@B39]; [@B7]). Senescent cells typically have an enlarged morphology and are most widely detected histochemically by an increased β-galactosidase activity known as senescence-associated β-galactosidase (SA-βGAL) ([@B31]), which is correlated to increased autophagy ([@B64]). Other biomarkers of senescence include increased expression of common senescence mediators such as p16, p21, p53, and p47ING1a ([@B37]; [@B52]). However, not all types of senescence result from telomere depletion. For example, up to 50% of mouse embryonic fibroblasts (MEF's) exhibit a senescence phenotype after a mere five passages resulting from oxygen sensitivity due to ROS-induced DNA damage ([@B49]). These interdependent features of cell cycle withdrawal, macromolecular damage, dysregulated metabolism and an altered senescence-associated secretory phenotype (SASP) have been described as hallmarks of the senescence phenotype, although no markers appear to be universal for all types of senescent cells. Therefore, to ensure the accurate identification of senescent cells it has been recommended by the International Cell Senescence Association that multiple markers be used in a three-step senescence identification protocol ([@B21]).

Mechanisms and Stimuli of Senescence {#S3}
====================================

A wide variety of stimuli affecting multiple molecular pathways are involved in the induction of a senescence based irreversible arrest in a state resembling G~0~ of the cell cycle in mammalian cells ([@B37]; [@B42]). These pathways are broadly classified into activating either p16 ([@B1]) or p21 ([@B8]) via the p53 tumor suppresser ([@B2]; [@B58]), and these signals converge to produce high levels of active hypophosphorylated Rb (Retinoblastoma) Tumor Suppressor ([@B13]; [@B52]). The tumor suppressive nature of cellular senescence is quite evident from the fact that tampering with levels of several of these oncogenes/tumor suppressors can lead to an escape from senescence ([@B11]). Broadly speaking, senescence can be triggered by numerous stresses including DNA-damage, oxidative stress, and oncogene induced stress. DNA-damage induced senescent cells are primarily observed in cancer patients post administration of radiotherapy and chemotherapy ([@B53]; [@B20]) and treatment results in accelerated telomere loss ([@B57]). Radiotherapy and Chemotherapy not only affect cancer tissue but also induce senescence in surrounding healthy tissue. Several observations have confirmed that exposure to topoisomerase inhibitors such as doxorubicin and etoposide induces senescence in primary diploid human fibroblasts *in vitro* ([@B53]). Studies have also shown that proteins of the SASP that are released from these surrounding senescent cells can induce an epithelial to mesenchymal transition (EMT) and hence promote malignancy in normally non-aggressive human breast cancer cell lines ([@B14]). Another important player in inducing senescence is ING1a from the *IN*hibitor of *G*rowth family of epigenetic regulators. Originally identified in 1996 by subtractive hybridization between cDNAs from normal mammary epithelial cells and transformed breast cancer cells, the *ING* family of genes are evolutionary conserved and ING proteins primarily localize to the nucleus ([@B19]). Our lab has shown that the ING1a isoform that is expressed in aging, but not low passage fibroblasts induces senescence when ectopically expressed several-fold faster (24--36 h) compared to other senescence inducing agents such as t-BHP (t-butyl hydroperoxide) and doxorubicin ([@B51]). We have shown that inhibition of endocytosis is one of the major mechanisms by which ING1a induces senescence ([@B52]; [@B51]). This occurs via affecting at least three independent members of the Rb pathway including Rb, p16^INK4a^, and p57^Kip2^. ING1a induces expression of Intersectin 2, subsequently altering the stoichiometry of the endocytosis apparatus and blocking signaling by mitogens ([@B52]). This represents a novel mechanism of senescence induction that is independent of telomere attrition and DNA damage signaling.

Cellular Senescence and Organismal Aging {#S4}
========================================

One of the hallmarks of mammalian aging is the accumulation of irreversibly arrested senescent cells in various tissues ([Figure 1](#F1){ref-type="fig"}). In a 2006 primate study, it was observed that senescent cells, as estimated by ATM activation do accumulate and can reach over 15% of the total cell population in aged individuals ([@B26]). In contrast to the vast majority of *in vitro* studies, this was one of the first studies showing a clear association between aging and the accumulation of senescent cells *in vivo*. Although this established a strong correlation, efforts were underway to establish causation between the accumulation of senescent cells and aging *in vivo*. In 2011, the Kirkland lab showed that removing p16^Ink4a^ positive senescent cells delayed age-related disorders and increased healthspan in a BubR1 progeroid accelerated model of aging mice ([@B4]). This was accomplished using a novel transgene composed of a p16^Ink4a^ promoter driving a FKBP--Caspase-8 fusion protein, which is selectively expressed in senescent cells and can be activated by the synthetic drug, AP20187. These transgenic mice showed delayed onset of sarcopenia, cataracts, significantly better exercise test scores and reduction in other age-related pathologies. Later studies confirmed the beneficial effects of senescent cell removal in wild type mice that showed increased median lifespan, delayed tumorigenesis and attenuated age-related multi-organ deterioration ([@B3]). Removal of senescent cells in mice has also been shown to attenuate markers of age-associated neurodegenerative diseases such as tau hyperphosphorylation and neurofibrillary tangle deposition ([@B9]). Since it is likely that even a small percentage of senescent cells can promote substantial deleterious effects, there may be natural mechanisms that clear these senescent cells *in vivo* to maintain overall fitness. One primary response to p53 activation in murine liver carcinoma was found to be the accumulation of senescent cells, which were subsequently shown to be cleared by the innate immune response ([@B63]). NK cells were also found to eliminate senescent cells *in vivo* by perforin (Prf) mediated granule exocytosis ([@B54]) and Prf1^--/--^ mice showed a 4X accumulation of senescent cells and a 21% decrease in median lifespan, which was alleviated by senescent cell clearance ([@B46]).
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Further evidence regarding the connection between cellular senescence and organismal aging comes from accelerated aging syndromes such as HGPS (Hutchinson-Gilford progeria syndrome). A higher proportion of HGPS fibroblasts are SA-β-Gal positive compared to fibroblasts from normal, age-matched controls, and they can be returned to a normal replicative state by exogenous expression of the TERT subunit of telomerase ([@B6]). Similarly, expressing progerin, the mutant lamin-A protein known to cause HGPS, in primary cells obtained from healthy individuals result in expression of senescent markers ([@B12]). These results suggest that progerin-induced telomere dysfunction may result in premature cellular senescence leading to the accelerated aging symptoms observed in HGPS patients.

Senolytics and Senomorphics {#S5}
===========================

Substantial evidence in the last decade connecting senescent cell accumulation, age-related ailments, and roles in lifespan and healthspan fueled the search for therapeutic compounds that could selectively target senescent cells. A transcriptomic analysis between senescent cells and proliferating cells showed increased expression of pro-survival/anti-apoptotic genes such as Bcl-xL (B-cell lymphoma-extra-large) a member of the Bcl-2 family of proteins that regulates programmed cell death by blocking caspase activation ([@B65]). This provided evidence to support the observation that senescent cells accumulate with age by being resistant to a variety of stresses that would normally induce apoptosis ([@B60]). Consistent with this idea, siRNAs to reduce Bcl-xL expression selectively reduced survival and viability in senescent cells while not affecting proliferating cells ([@B66]). Quercetin and Dasatinib were obtained as hits from a drug screen based on these observations ([@B27]). Quercetin: a flavonoid and Dasatinib: an anticancer agent, are known inhibitors of a variety of tyrosine kinases ([@B30]; [@B40]). These compounds form one of the first discovered members of the senolytic class of drugs that selectively induce apoptosis in senescent cells. Four years after their initial identification as candidate senolytics, a Dasatinib + Quercetin combination was reported to decrease the senescent cell burden in humans as part of a Phase-1 clinical trial in diabetic kidney disease patients ([@B27]). This 2019 study was the first peer-reviewed study to demonstrate the efficacy of senolytics to decrease senescent cell burden in humans. This was carried out after an initial pilot study in early 2019 in 14 idiopathic pulmonary fibrosis (IPF) patients was completed to evaluate the feasibility of implementing a senolytic treatment ([@B33]). What now remains to be determined is whether future clinical trials will demonstrate any positive medical outcomes resulting from decreased senescent cell burden in diabetes and other age-associated ailments.

Another senolytic strategy is the inhibition of the interaction between Mouse Double Minute 2 (MDM2) and p53 that usually results in the ubiquitination and proteasomal degradation of p53 ([@B45]; [@B59]). The MDM2 protein acts as an E3 ubiquitin ligase and facilitates p53 degradation. *MDM2* contains two promoters: P1 and P2. P1 is constitutively active at low levels while the P2 promoter has p53 binding sites and acts as a negative regulator of p53 ([@B28]). The MDM2 antagonists Nutlin-3a and MI-63 have been shown to increase p53 levels and attenuate the secretory phenotype of senescent cells (SASP) ([@B62]). These represent a new class of compounds known as "Senomorphics," which attenuate the expression of cytokines such as IL-6 (Interleukin-6) that make up the SASP. UBX0101, a compound from the Unity Biotechnology pipeline is another promising senolytic that inhibits the MDM2/p53 interaction and is currently undergoing Phase 1 clinical trial against osteoarthritis. UBX0101 administration was reported to decrease classical osteoarthritis-related phenotypes such as cartilage erosion and joint pain in mice by p53-mediated clearing of senescent cells. This study suggested that senescent cells might promote osteoarthritis ([@B32]), another medically relevant age-related pathology.

Heat Shock Protein 90 (HSP90) might represent another target for senolysis. This protein is one member of a large family of chaperones that help other proteins to fold and refold after cell stress and is indirectly involved in a wide variety of cellular processes such as DNA repair, heat stress response and neurodegenerative pathologies ([@B55]). While HSP90 levels remain relatively similar in senescent and non-senescent cells, AKT (Protein Kinase B), which is a downstream effector of HSP90 is highly expressed in senescent cells. Inhibiting HSP90 destabilizes AKT and results in increased apoptosis ([@B34]). HSP90 inhibitors such as 17-DMAG were discovered through a screen for senolytic compounds based on SA-βGAL positive cell count as an endpoint. 17-DMAG was further shown to be senolytic *in vivo* by decreasing p16 positive cells and extending healthspan in Ercc1^--/Δ^ mice ([@B18]).

The Next Generation of Senolytics {#S6}
=================================

Since senescence is a complex phenotype involving multiple pathways and proteins, it is unlikely that a single senolytic compound targeting a single protein will be able to eliminate all types of senescent cells. For example, Quercetin is more selective against senescent human endothelial cells, while Dasatinib is far more effective against senescent human primary preadipocytes ([@B27]). Similarly, while Navitoclax, a senolytic agent targeting the Bcl-2 family of proteins is selective against senescent human umbilical vein epithelial cells (HUVECs) and IMR90 human lung fibroblasts, it is not particularly effective against primary human preadipocytes ([@B65]). Senolytic compounds that target senescent cells more broadly while maintaining low cytotoxicity by increased selectivity solely for cells that are truly senescent are therefore of great interest! Elevated activity of the lysosomal β-galactosidase, which is a nearly universal characteristic of senescent cells ([@B38]) and has been exploited as a senescence biomarker can also be utilized for drug selectivity against a wide range of senescent cells. One example is a drug delivery system utilizing encapsulation of cytotoxic drugs with galacto-oligosaccharides ([@B44]). These capsules that can be loaded with a variety of cytotoxic compounds, take advantage of the high senescent cell lysosomal β-galactosidase activity to preferentially release their cargo within senescent cells. A very recent study also used a similar strategy involving galactose-modified prodrug. Here, preferential processing of galactose-modified duocarmycin (GMD), a cytotoxic conjugate, was used to eliminate a wide variety of senescent cell types ([@B22]). Targeting cell surface proteins enriched in senescent cells such as DPP4 (dipeptidyl peptidase 4) can also be used to enhance selectivity ([@B36]). Another cell surface protein, the CD9 receptor has also been used to target senescent cells and their secretory phenotype with anti-CD9 monoclonal antibody encapsulated, lactose-wrapped nanoparticles, loaded with rapamycin as the payload ([@B56]). These nanoparticles have dual selectivity toward senescent cells based on both increased CD9 receptors on the cell surface and increased lysosomal β-galactosidase expression.

Conclusion {#S7}
==========

The role of cellular senescence in organismal aging has been well established in the past two decades in a variety of organisms ([@B17]; [@B25]; [@B43]). From initial thoughts indicating that senescence served primarily as an anti-cancer mechanism, we note the emerging view of senescence also acting as a driving force behind a wide variety of age-related pathologies ([@B16]). More recent studies in the last decade, which resulted in the development of transgenes and chemical perturbagens, have finally given us the tools to selectively manipulate the quantity of senescent cells *in vivo*. Thorough characterization of their deleterious secretory phenotype, that varies in different cell types, continues to improve our understanding of how they contribute to the wide variety of age-related diseases observed in our populations. Finally, as the first Senolytics enter clinical trials, we are on the cusp of establishing a translational bridge between cellular senescence and organismal aging ([@B42]; [@B10]; [@B21]) that may help ameliorate the burden of many age-related pathologies.

Author Contributions {#S8}
====================

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by a grant to KR from the Canadian Institutes of Health Research (MOP-133646).

[^1]: Edited by: Vassilis G. Gorgoulis, National and Kapodistrian University of Athens, Greece

[^2]: Reviewed by: Chiaki Takahashi, Kanazawa University, Japan; Brian Gabrielli, The University of Queensland, Australia

[^3]: This article was submitted to Cell Growth and Division, a section of the journal Frontiers in Cell and Developmental Biology
